NCT02961218 - Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

June 27, 2019

Study Completion Date

April 27, 2020

Conditions

Sickle Cell Anemia

Interventions

DRUG

ACZ885

Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects

DRUG

Placebo

Monthly doses of placebo to match the administered dose of canakinumab s.c.

Trial Locations (15)

2193

Novartis Investigative Site, Johannesburg

20246

Novartis Investigative Site, Hamburg

27834

Novartis Investigative Site, Greenville

30329

Novartis Investigative Site, Atlanta

30912

Novartis Investigative Site, Augusta

33343

Novartis Investigative Site, Mersin

1834111

Novartis Investigative Site, Afula

M5G 1X8

Novartis Investigative Site, Toronto

01330

Novartis Investigative Site, Adana

06100

Novartis Investigative Site, Ankara

WS11 5XY

Novartis Investigative Site, Wolverhampton

E1 1BB

Novartis Investigative Site, London

NW1 2BU

Novartis Investigative Site, London

SE1 7EH

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London